

UNDERSTANDING THE PATIENT PERSPECTIVES OF POST-DISCHARGE CARE AND IMPACT OF TREATMENT IN THE FIRST YEAR POST-ACUTE MYOCARDIAL INFARCTION

M. Cecilia Bahit^{1,2}, Serge Korjian^{2,3}, Gerald Chi³, Yazan Daaboul^{2,3}, Ginger Jiang^{2,3}, Deepak L. Bhatt⁴, Roxana Mehran⁴, **Paul Nara**⁵, Alka Shaunik⁵, C. Michael Gibson^{2,3}

¹INECO Neurociencias, Rosario, Argentina; ²Baim Institute for Clinical Research, Boston, MA, USA; ³Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; ⁴Icahn School of Medicine at Mount Sinai, New York, NY, USA; ⁵CSL Behring, King of Prussia, PA, USA.

Background and objectives

- Patients have a high risk of recurrent cardiovascular events following an acute myocardial infarction (AMI), particularly in the initial 90 days post-AMI¹
- Following an AMI, long-term guideline-directed secondary preventative medical therapies are prescribed to patients to reduce their cardiovascular risk²
- Understanding treatment experiences post-AMI from patients' perspectives is important for optimizing care

Methods

- In this institutional review board-approved study, patient perspectives post-AMI were gathered via an online, self-administered survey
- Adults in the US who experienced an AMI in the year prior to survey completion were eligible for inclusion
- Data were collected from October 30 to December 30, 2022
- Patients were grouped according to the timing of their latest AMI:
 - <90 days:** AMI within 90 days prior to survey completion
 - >90 days:** AMI between 90 days and 1 year before survey completion

Table. Key demographics and characteristics


	Total respondents N=151
Age (years), median (IQR)	50 (40–60)
Sex, n (%)	
Male	104 (69)
Female	46 (30)
Transgender	1 (1)
Most recent MI, n (%)	
<90 days ago	58 (38)
>90 days to 1 year ago	93 (62)
Number of MIs experienced per person, median (IQR)	1 (1–2)
Comorbidities, n (%)	
Arterial hypertension	131 (87)
Hypercholesterolemia	116 (77)
Chronic anxiety	81 (54)
Obesity	76 (50)
Diabetes	64 (42)
Other	44 (29)
None	1 (1)

IQR, interquartile range; MI, myocardial infarction

Results

- Of the 151 patients in the overall cohort, 69% were male and the median age was 50 years (**Table**)
 - The most common comorbidities were arterial hypertension (87%) and hypercholesterolemia (77%)
 - In total, 58 patients had their latest AMI <90 days ago and 93 patients had their latest AMI >90 days prior to survey completion
- Approximately 75% of patients underwent ≥1 procedure to treat their latest AMI
 - Of those who did not undergo surgery to treat their AMI, 23% were managed with medication and 2% did not receive medical or surgical treatment
- A higher proportion of patients in the >90 days group versus the <90 days group received post-discharge, standard-of-care pharmacotherapies (**Figure 1**)

Figure 1. Medications patients were prescribed post-AMI in the <90 days and >90 days groups




Conclusions

- Patients within 1 year post-AMI exhibit considerable disease burden on their lives, with treatment burden being a substantial negative contributor
- Understanding the changing needs of patients will inform development of patient-preferred strategies that improve adherence to guideline-recommended care, particularly in the initial, high-risk 90-day period post-AMI

Results


- Overall, 42 (28%) respondents reported forgetting to take their secondary preventative medication in the past month (**Figure 2**)
- A higher proportion of patients in the <90 days group felt that remembering to take their medication was “tedious” versus the >90 days group (50% vs. 37%, p=0.04)

Figure 2. Treatment adherence in the overall cohort (N=151)



- Regarding financial burden, 43% of patients in the <90 days group reported an extreme impact on household finances compared with 25% in the >90 days group (**Figure 3**)
- Treatment/prescriptions, tests, and AMI-related appointments were the main out-of-pocket costs in the <90 days group, whereas lost income was most commonly reported in the >90 days group

Figure 3. Impact on household finances post-AMI



References:

1. Chi G, et al. Clin Cardiol. 2022;45(3):299–307; 2. Byrne RA, et al. Eur Heart J. 2023;44(38):3720–826.

Presenter disclosures:

The study was sponsored by CSL Behring in collaboration with the Baim Institute. Dr. Nara is an employee of CSL Behring.

Poster presented at The Professional Society for Health Economics and Outcomes Research (ISPOR), Atlanta, GA, May 5–8, 2024.

